Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EDP-494

Small molecule · developed by Enanta Pharmaceuticals

Phase 1 Most advanced trial (none active)

ENTA Developer

1 Registered trials

What is EDP-494?

EDP-494 is a drug supplied as 10, 100 and 200 mg capsules. It is studied in hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Infectious disease
Developer: Enanta Pharmaceuticals, Inc (ENTA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02652377	Phase 1	Hepatitis C	Completed	ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C

More from Enanta Pharmaceuticals

EDP-235 Phase 2 EDP-297 Phase 1 EDP-305 Phase 2 EDP-322 Phase 1 EDP-323 Phase 2 EDP-514 Phase 1 EDP-721 Phase 1 EDP-788 Phase 1 EDP-978 Phase 1 EDP239 Phase 1 Zelicapavir Phase 2

Sources

ClinicalTrials.gov NCT02652377

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.

Follow ENTA, the company behind EDP-494

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z